Latest News | Gland Pharma Gets USFDA Nod for Generic Ophthalmic Solution

New Delhi, Apr 30 (PTI) Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat conditions related to high pressure in the eye.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Latanoprostene Bunod Ophthalmic Solution, (0.024 per cent), the drug firm said in a statement.

Also Read | 8th Pay Commission Chairman: Who Will Head 8th CPC? Who Are the Members of the New Pay Commission? As Appointment Process Starts, Here's What We Know So Far.

The company's product is bioequivalent and therapeutically equivalent to Bausch and Lomb, Inc's Vyzulta ophthalmic solution, it added.

The product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Also Read | Who Was the Chairman of 7th Pay Commission? How Many Members Were in 7th CPC? As Govt Begins Process To Form 8th Pay Commission, Here's All You Need To Know About Previous Panel.

The company is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity, Gland Pharma said.

According to IQVIA, the product had sales of around USD 171 million in the US for the 12 months ending February 2025.

Shares of Gland Pharma on Wednesday ended 1.04 per cent down at Rs 1,398.35 apiece on the BSE.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)